ApoAI Blocking Peptide
Cayman Chemical Item Number 13079
Apolipoprotein A-I; Apolipoprotein AI
Description
ApoAI is a major protein component in high-density lipoproteins (HDLs). It acts as an acceptor for sequential transfers of phospholipids and free cholesterol from peripheral tissues and transports cholesterol to the liver and other tissues for excretion and steroidogenesis.1 Serum ApoAI levels are inversely related to the risk of developing atherosclerosis.2 Loss-of-function mutations are causes of diseases such as HDL deficiency type 1 (or Tangier disease) and type 2 (familial hypoalphalipoproteinemia), and systemic non-neuropathic amyloidosis.3,4 ApoAI is comprised of a single polypeptide chain of 243 amino acids residues with an estimated molecular weight of 28 kDa. Cayman’s ApoAI Polyclonal Antibody detects the protein by Western blot analysis in tissue/cell samples such as liver, intestine, and Hep-G2 cells.
1
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
2
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
3
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
4
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
| Synonyms |
- Apolipoprotein A-I
- Apolipoprotein AI
|
| Formulation |
200 µg of peptide in 200 µl TBS, pH 7.2, containing 0.1% BSA and 0.02% sodium azide |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
Wet ice
in continental US; may vary elsewhere
|
Background Reading
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
Show all 4
Hide all but first 3
|
Pricing updated 2012-05-26.
Prices are subject to change without notice.
To ask for assistance with one of our products please contact a Technical Support Scientist.
Warning This product is not for human or veterinary use.
Downloads
Batch-specific Information
Login
to access batch-specific information
|